STAT Plus: New drug combination extends survival with advanced kidney cancer. It’s poised to enter a competitive treatment market
Patients with advanced kidney cancer live longer when treated with a combination of drugs from Bristol Myers Squibb and Exelixis compared to an older medicine, according to new clinical trial results reported Sunday.
Convincing physicians to prescribe the new combination regimen for kidney cancer patients, though, will face a challenge: equally effective treatments already in use.
Continue to STAT Plus to read the full story…
